Generic Name and Formulations:
Meloxicam 7.5mg, 15mg; tabs.
Boehringer Ingelheim Pharmaceuticals
Indications for MOBIC:
Osteoarthritis. Rheumatoid arthritis. Juvenile rheumatoid arthritis pauciarticular and polyarticular course.
Use lowest effective dose for shortest duration. ≥18yrs: 7.5mg once daily; max 15mg once daily. Hemodialysis: max 7.5mg/day. Not interchangeable with other forms of oral meloxicam.
Use lowest effective dose for shortest duration. <2yrs or <60kg: not recommended. JRA: ≥2yrs or ≥60kg: 7.5mg once daily. Not interchangeable with other forms of oral meloxicam.
Aspirin allergy. Coronary artery bypass graft surgery.
Risk of serious cardiovascular and gastrointestinal events.
Increased risk of serious cardiovascular events (including MI, stroke). Avoid in recent MI, severe heart failure; if necessary, monitor. Increased risk of serious GI adverse events (including inflammation, bleeding, ulceration, perforation). History of ulcer disease and/or GI bleeding. Hypertension; monitor BP closely. Hepatic or renal impairment. Discontinue if signs/symptoms of liver disease develop, or if abnormal LFTs persist or worsen. Dehydration. Hypovolemia. Advanced renal disease: not recommended. Hyperkalemia. Coagulation disorders. Monitor CBCs, blood chemistry, hepatic, and renal function in long-term therapy. Pre-existing asthma. May mask signs of infection or fever. Discontinue at 1st sign of rash or any other hypersensitivity. Women with difficulties conceiving or undergoing investigation of infertility: not recommended. Elderly. Debilitated. Labor & delivery. Pregnancy (≥30 weeks gestation; avoid). Nursing mothers.
Avoid concomitant aspirin, salicylates (eg, diflunisal, salsalate) or other NSAIDs. Increased risk of GI bleed with anticoagulants, antiplatelets, oral corticosteroids, SSRIs, SNRIs, smoking, alcohol, or prolonged NSAID therapy; monitor. May antagonize, or increase risk of renal failure with diuretics (eg, loop or thiazides), ACE inhibitors, ARBs, or β-blockers; monitor closely. May potentiate lithium, methotrexate, cyclosporine; monitor for toxicity. Concomitant with pemetrexed may increase risk of pemetrexed-associated myelosuppression, renal, and GI toxicity.
Diarrhea, upper RTI, dyspepsia, influenza-like symptoms; cardiovascular thrombotic events, GI ulcer/bleed, hepatotoxicity, renal toxicity, edema, hypersensitivity reactions, anemia.